Humacyte (NASDAQ:HUMA) Releases Earnings Results, Misses Expectations By $0.05 EPS

Humacyte (NASDAQ:HUMA) issued its quarterly earnings data on Wednesday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.05), FiscalAI reports. Humacyte had a negative net margin of 4,836.06% and a negative return on equity of 2,914.18%. The company had revenue of $0.41 million during the quarter, compared to analysts’ expectations of $1.12 million.

Here are the key takeaways from Humacyte’s conference call:

• V012 Phase III interim results exceeded expectations in female dialysis patients: ATEV recipients had 91 more catheter-free days than AV fistula patients, with significantly fewer infections. Humacyte plans to file a supplemental BLA in November 2026 and is targeting a potential launch in late Q2 2027 if priority review is granted.
• Humacyte is rebuilding its SYMVESS commercial organization with vascular-surgery-focused sales personnel, a national accounts strategy, streamlined hospital value-analysis processes, and introductory pricing. At least 20 major U.S. healthcare systems are reportedly in the process of adopting the product, although meaningful benefits are expected mainly in the second half of 2026.
• The FDA accepted Humacyte’s IND for its smaller-diameter CTEV vessel in coronary artery bypass grafting, and the company expects to begin a 10-patient Phase IIa study during the current quarter. Management said initial CTEV manufacturing will not materially constrain ATEV commercial production.
• Financial results continued to reflect commercialization and manufacturing costs: second-quarter revenue was only $0.4 million, cost of goods sold reached $1.2 million including a $0.7 million inventory reserve, and net loss was $36.8 million. Cash, cash equivalents, and restricted cash totaled $80.3 million at June 30, 2026, supported in part by equity-sale proceeds.

Humacyte Stock Down 6.3%

Humacyte stock opened at $0.67 on Thursday. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.55. The stock’s fifty day simple moving average is $0.81 and its 200-day simple moving average is $0.91. The company has a current ratio of 3.93, a quick ratio of 3.32 and a debt-to-equity ratio of 5.46. The firm has a market capitalization of $147.64 million, a P/E ratio of -1.17 and a beta of 2.53.

More Humacyte News

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: Strong Phase 3 dialysis results: In the V012 trial of female dialysis patients, Humacyte’s acellular tissue-engineered vessel (ATEV) outperformed traditional AV fistula access. Patients receiving ATEV had an average of 91 additional catheter-free days, while infection rates were 6 versus 23 per 100 patient-years. The data met the primary efficacy endpoint and supports a planned supplemental BLA filing in the second half of 2026. Humacyte Reports Stronger Phase 3 Dialysis Results in Women
• Positive Sentiment: Potential regulatory and commercial milestones: Management expects the FDA to issue a PDUFA decision around May 2027, with a possible dialysis-access launch by the end of the second quarter of 2027. The FDA also accepted Humacyte’s IND for a first-in-human study of its coronary tissue-engineered vessel, with a Phase 2a CABG study planned for the third quarter of 2026. Humacyte Targets November sBLA Filing
• Positive Sentiment: Early Symvess adoption improved: Second-quarter product sales rose to $0.4 million from $0.1 million a year earlier. Humacyte is rebuilding its commercial organization and adding hospital pricing, education and market-access initiatives to increase utilization. Humacyte Second-Quarter Financial Results
• Positive Sentiment: Additional funding: Humacyte raised $57.5 million through a public offering, providing capital for commercialization, regulatory filings and pipeline development.
• Neutral Sentiment: Cash runway remains a key focus: The company reported $80.3 million in cash, cash equivalents and restricted cash at June 30, while cost reductions are expected to save approximately $14.3 million during 2026.
• Negative Sentiment: Quarterly results missed expectations: Humacyte reported a second-quarter loss of $0.16 per share versus the consensus loss estimate of $0.11, while revenue of $0.41 million fell well short of the $1.12 million estimate. Humacyte Reports Q2 Loss and Misses Revenue Estimates
• Negative Sentiment: Large losses and weak near-term profitability: Net loss was $36.8 million, and cost of goods sold increased to $1.2 million despite limited revenue. The public offering also increases the risk of shareholder dilution.

Analyst Ratings Changes

A number of equities research analysts have weighed in on HUMA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Humacyte in a research report on Wednesday, July 8th. HC Wainwright upped their price objective on shares of Humacyte from $3.00 to $4.00 and gave the stock a “buy” rating in a report on Thursday, June 11th. Wall Street Zen raised shares of Humacyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. TD Cowen cut their target price on Humacyte from $1.50 to $1.25 and set a “buy” rating on the stock in a research report on Wednesday, June 17th. Finally, Benchmark upped their price target on Humacyte to $2.00 and gave the stock a “speculative buy” rating in a research note on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.25.

Insider Activity at Humacyte

In related news, Director Kathleen Sebelius purchased 56,818 shares of Humacyte stock in a transaction on Tuesday, May 19th. The shares were bought at an average price of $0.88 per share, with a total value of $49,999.84. Following the transaction, the director directly owned 148,025 shares of the company’s stock, valued at approximately $130,262. This trade represents a 62.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dale A. Sander sold 45,887 shares of Humacyte stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $0.90, for a total value of $41,298.30. Following the completion of the transaction, the chief financial officer owned 267,213 shares of the company’s stock, valued at $240,491.70. The trade was a 14.66% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of Humacyte

Several hedge funds have recently added to or reduced their stakes in the company. Atom Investors LP acquired a new position in Humacyte during the 4th quarter worth approximately $25,000. Financial Advisors Network Inc. acquired a new position in shares of Humacyte during the second quarter worth $28,000. Prudential Financial Inc. acquired a new position in shares of Humacyte during the second quarter worth $28,000. Equitable Holdings Inc. purchased a new position in Humacyte in the third quarter valued at $29,000. Finally, Imprint Wealth LLC acquired a new stake in Humacyte in the third quarter valued at $33,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.